Jazz Wades Into Cannabinoid Weeds With $7.2bn GW Buy

Epilepsy Drug Epidiolex Adds To Sleep, Oncology Franchises

 
• By Mandy Jackson

Priced at a 50% premium to GW’s value, the deal will reduce the percentage of Jazz’s drug sales coming from Xyrem, provide double-digit revenue growth and expand the R&D pipeline to 19 programs.

Merging, two merchants push the red squares and other squares together
Sales of Epidiolex last year equal almost a quarter of Jazz's expected 2020 revenue • Source: Shutterstock

More from Deals

More from Business